Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027772 | 0.86 | LOXL2 (0.33) | ACACBNPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL14046218 | 0.82 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2SCN4AALDH1A1 | |
| SCHEMBL14046224 | 0.82 | ACACB (0.38) | ACACBNPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL2707208 | 0.78 | NPC1 (0.45) | ACACBNPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL23775746 | 0.78 | ACACB (0.39) | ACACBNPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL21981998 | 0.78 | ACACB (0.36) | ACACBNPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL19803743 | 0.78 | CASR (0.32) | NPC1RAB9ASMN1; SMN2SCN4ACASR | |
| SCHEMBL31321369 | 0.73 | MAPT (0.51) | NPC1RAB9ASMN1; SMN2SCN4ATP53 | |
| SCHEMBL15935289 | 0.73 | LOXL2 (0.40) | ACACBNPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL24476894 | 0.72 | S1PR1 (0.43) | ACACBRAB9ASMN1; SMN2LOXL2CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021160132-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2021-08-19 | — | — | WO | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | ACACB 203/4885NPC1 37/4885RAB9A 2515/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | ACACB 2037/4885NPC1 1283/4885RAB9A 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.